Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NPC-1C/NEO-102 · 1 trial · 2 indications
Using the recommended phase 2 dose (RP2D) evaluate the overall survival (OS) associated with administration of NPC-1C (NEO-102) in subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer or metastatic colorectal cancer that express NPC-1C target on tumor.
| Arm | Type | Description |
|---|---|---|
| NPC-1C/NEO-102 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NPC-1C/NEO-102 | DRUG | Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity. |
INCLUSION CRITERIA: * Age: \>/= 18 * Diagnosis: * Histologically confirmed recurrent, locally advanced unresectable or metastatic adenocarcinoma of the pancreas who have progressed after front line chemotherapy, OR * Histologically confirmed metastatic colorectal adenocarcinoma who have progre...
Top 20 of 68 competitors
NPC-1C/NEO-102 is an investigational small molecule being studied for the treatment of metastatic pancreatic cancer. It is also being evaluated in metastatic colorectal cancer. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
NPC-1C/NEO-102 is being developed by Precision BioSciences, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol DTIL. Precision BioSciences is responsible for the clinical development and potential commercialization of this investigational therapy.
NPC-1C/NEO-102 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is still in the early stages of clinical testing to evaluate its safety and potential efficacy.
NPC-1C/NEO-102 has been studied in one completed clinical trial, identified as NCT01040010. This trial, titled QUILT-3.019, was a Phase 2 study of the NPC-1C chimeric monoclonal antibody for pancreatic and colorectal cancer. The trial enrolled 94 participants and was conducted in the United States.
Yes, NPC-1C and NEO-102 refer to the same investigational drug. The drug is identified by both names in clinical development. It is being studied for its potential use in treating metastatic pancreatic cancer and metastatic colorectal cancer.